However, by binding to the catalytic site of ALKBH5, compound 19 competitively downregulates the expression of ALKBH5, inducing a decrease in CD73 expression, and reducing the invasion and migration of GBM cells U87-MG. The gene discussed is ALKBH5; the disease is glioblastoma.